Cheratussin AC and Dabrafenib Mesylate

• Generic Name: codeine / guaifenesin
• Dosage Forms: n.a.
• Other Brand Names: Allfen CD, Cheracol with Codeine, Cheratussin AC, Codar GF, Duraganidin NR, Guaiatussin AC, Iophen-C NR, Mar-cof CG, M-Clear, Mytussin AC, Relcof C, Guaifenesin AC Liquid, Iophen C-NR, Mar-cof CG, Ninjacof-XG, Virtussin A/C

Codeine is a narcotic cough suppressant. It affects the signals in the brain that trigger cough reflex.

Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.

Cheratussin AC is a combination medicine used to treat cough and chest congestion caused by allergies, the common cold, or the flu.

Cheratussin AC will not treat a cough that is caused by smoking, asthma, or emphysema.

Cheratussin AC may also be used for purposes not listed in this medication guide.

• Generic Name: dabrafenib
• Dosage Forms: n.a.
• Other Brand Names: Tafinlar

Used in combination with trametinib as adjuvant therapy following complete resection of melanoma with BRAF V600E or V600K mutation and nodal involvement.

Used as a single agent for the treatment of unresectable or metastatic melanoma in patients with BRAF V600E mutation (designated an orphan drug by FDA as monotherapy for this use).

Used in combination with trametinib for treatment of unresectable or metastatic melanoma in patients with BRAF V600E or V600K mutation (designated an orphan drug by FDA when used in combination for this use).

FDA-approved diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E mutation prior to initiation of monotherapy; also required to confirm presence of BRAF V600E or V600K prior to initiation of combination therapy.

Not recommended for use in patients with wild-type BRAF melanoma; safety and efficacy not established. (See Tumor Promotion in Wild-Type BRAF Tumors under Cautions.)

Used in combination with trametinib for treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutation (designated an orphan drug by FDA when used in combination for this use).

FDA-approved diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E mutation prior to initiation of therapy.

Not recommended for use in patients with wild-type BRAF NSCLC; safety and efficacy not established. (See Tumor Promotion in Wild-Type BRAF Tumors under Cautions.)

Used in combination with trametinib for treatment of locally advanced or metastatic anaplastic thyroid cancer in patients with BRAF V600E mutation when no satisfactory locoregional treatment options are available (designated an orphan drug by FDA when used in combination for this use).

FDA-approved diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E mutation prior to initiation of therapy.

Not recommended for use in patients with wild-type BRAF anaplastic thyroid cancer; safety and efficacy not established. (See Tumor Promotion in Wild-Type BRAF Tumors under Cautions.)